Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Saba Capital Management has reached an agreement with relevant funds to withdraw its director nominations that were originally scheduled for the 2026 annual fund meeting.

Saba Capital Management has reached an agreement with relevant funds to withdraw its director nominations that were originally scheduled for the 2026 annual fund meeting.

老虎证券老虎证券2026/06/02 22:04
Show original
At the same time, the hedge fund has agreed to abide by a “standstill” clause lasting until 2028. Under the terms of the agreement, Saba Capital commits not to initiate proxy contests or undertake other confrontational actions during the specified period. This move aims to ease tensions between both parties and create a stable environment for future cooperation.The settlement involves several funds, including the Voya Asia Pacific High Dividend E and the Voya Emerging Markets High Divide. The agreement marks the end of a long-standing dispute.Saba Capital is well-known for actively promoting reforms in closed-end funds, often pressuring management by nominating board candidates. The new agreement will temporarily put such actions on hold, providing fund managers with operational certainty.Analysts point out that such standstill agreements are not uncommon in the fund industry and typically help avoid costly proxy battles. Both parties look forward to achieving joint growth in fund net asset value and shareholder interests during the term of the agreement.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data

On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)

路透社•2026/10/08 18:26

BUZZ - Reports suggest Starbucks had discussed a deal, Chipotle shares rise

Latest Updates October 8 - Chipotle Mexican Grill shares (CMG.N) surged by as much as 8.55% to $33.40, while Starbucks (SBUX.O) shares once dropped 6.66% to $87.35. The Financial Times, citing insiders, reported that Starbucks (SBUX) had considered acquiring Chipotle (link). The coffee giant's stock has fallen to its lowest point since March. According to the report, the progress of the acquisition plan remains unclear; both Starbucks and Chipotle did not immediately respond to Reuters' requests for comment. If the deal goes through, CEO Brian Niccol would return to lead the Mexican grill chain he ran before joining the coffee giant two years ago. "For SBUX, we think investors would view this as a distraction for management's time and energy—after all, there is still much work to be done to revive the Starbucks brand, particularly concerning the fundamentals of same-store sales in North America, as the company gradually exhausts easily achievable growth points through 2027 and beyond," said RBC Capital Markets analyst Logan Reich. According to data from the London Stock Exchange Group (LSEG), CMG has a market capitalization of about $39 billions, while SBUX is valued at $107 billions. As of the close of the last trading day, SBUX has risen about 11% year-to-date, while CMG has fallen by 17%. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may be inaccurate or lack contextual nuances, Reuters does not guarantee the accuracy of translated texts, which are provided solely for reader convenience. Reuters accepts no liability for any loss or damage arising from the use of automated translations.)

路透社•2026/10/08 18:16